Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$vrx...$15.38...Excellent play here on strong volume..
Good morning everyone..
$PMCB PharmaCyte's CEO Discussed Development of its Pancreatic Cancer Therapy http://pharmacyte.com/pharmacytes-ceo-discusses-development-of-its-pancreatic-cancer-therapy/
$AMRS "Amyris’s µPharm™ discovery and production platform opens up new possibilities for drug discovery using proven synthetic biology to create compound libraries containing natural and natural product-like compounds in a scalable production organism.
Create – Discover – Deliver
Using a combinatorial rational design process and proprietary yeast strains and strain engineering technology for production of terpenoids, Amyris scientists build libraries of microorganisms that produce natural and novel compounds of pharmaceutical relevance. These compounds were previously difficult or impossible to obtain through traditional chemical synthesis.
These libraries can be generated in strains engineered to allow detection or selection of ligands with affinity to defined pharmaceutical targets. Once yeast strains with lead compounds are identified, the same combination of heterologous genes can be transferred into a yeast host optimized for terpenoid production at pilot or commercial scales.
Benefits
Nearly half of all drugs approved since 1994 are based on compounds present in natural products.
Many pharmaceutical companies have reduced or eliminated natural product drug discovery screening due to difficulties in access, complexities of natural product chemistry and purification, and challenges in supply.
There are over 30,000 known terpenoids in nature, and many terpenoid and terpene-derived molecules are biologically active signaling agents.
Amyris has developed a state-of-the-art platform for generating and screening diversity based on over a decade of experience in producing terpenoids.
Using combinatorial design, Amyris can produce more than 100,000 novel terpenoids derived from natural terpene scaffolds."
https://amyris.com/collaborations/%CE%BCpharm/
$DNRG 'Dominovas Energy Corp #HydrogenFuelCells! Dominovas Energy Welcomes Appointment of Special Advisor for Renewable Energy Projects http://dominovasenergy.com/dominovas-energy-to-engage-with-shareholders-and-investors-via-conference-call/
$AMRS Amyris - A Juggernaut In The Making
http://seekingalpha.com/article/3999958-amyris-juggernaut-making
$AMRS *Amyris Three-Year, Multi-Million-Dollar Contract from U.S. Department For Cellulose-Derived Farnesene; Expects To Receive Several Million Dollars Over Term Of Contract http://investors.amyris.com/releasedetail.cfm?releaseid=983371
$AMRS & Johnson & Johnson $JNJ via Janssen. Recently entered into research agreement with commercial license option with Janssen Biotech, facilitated by Johnson & Johnson Innovation, to use Amyris’s µPharm platform for rapid integrated discovery and production of therapeutic compounds thereby opening a new area of compounds previously not accessible for new drug discovery. “We expect to sign one more collaboration by the end of the year, ending at the high-end of our range, to develop a library of natural and natural like of therapeutic compounds, which nature has the potential to provide and we have the ability to produce.”
http://www.biofuelsdigest.com/bdigest/2016/08/14/amyris-the-new-colossus-aims-to-unlock-its-golden-door/
$DNRG Dominovas Energy Corporation's focus is on commercializing cutting edge technology that accelerates the transition to a fuel cell economy. Our fuel cell division drives the entire fuel cell systems supply chain, reducing overall manufacturing costs, and rapidly accelerating the adoption of efficient and cost effective fuel cell power systems worldwide. At the heart of the Dominovas Energy Corporation's Fuel Cell Division is the RUBICONTM Series employing SOFC. The proprietary RUBICONTM Series Fuel Cells are capable of reforming and converting multiple fuel stocks including but not limited to, diesel, LNG, methanol, bio-diesel and hydrogen into multiple customizable power output channels. http://www.otcmarkets.com/stock/DNRG/profile
$FDBL Loading Zone... Penny Land?
Amrs.. .52..Excellent close yesterday..
$AMRS Billionaire Bill Gates Malaria interest. AMRS can make vaccine for 1/10 cost. Spring of 2016, Bill & Melinda Gates Foundation bought $AMRS for $1.14 per share. Anything under is a #Gift imo. https://biz.yahoo.com/e/160513/amrs8-k.html
Amrs.. .49..continues to get stronger here..
Amrs..excellent news...huge play here..
$AMRS Gingko. Entered into an Initial Strategic Partnership Agreement with Ginkgo Bioworks to accelerate commercialization of bio-based ingredients and establish clear leadership in industrial biotechnology with a combined offering that we consider unparalleled. In connection with the agreement, a license fee of $15 million was paid on July 25, 2016, to Amyris in exchange for use of certain Amyris technology and the parties agreed to pursue the negotiation and execution of a definitive partnership agreement that includes significant value sharing. The partnership is expected to deliver more new ingredients into the global market over the next three years than the entire industry has achieved in the last 10 years.
http://www.biofuelsdigest.com/bdigest/2016/08/14/amyris-the-new-colossus-aims-to-unlock-its-golden-door/
$DNRG Dominovas Energy Welcomes Appointment of Special Advisor for Renewable Energy Projects http://dominovasenergy.com/dominovas-energy-welcomes-appointment-of-special-advisor-for-renewable-energy-projects/
$AMRS Amyris "Amyris delivers high-performance renewable products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability.
We developed innovative microbial engineering and screening technologies that modify the way microorganisms process sugars. With our innovative bioscience technology and established fermentation processes, we convert plant-sourced sugars into renewable molecules for multiple applications.
Our story began over a decade ago, when Amyris was founded with a vision of making a positive impact on the world through science. We first used our proprietary process to convert plant-sugars into an alternative, lower cost, stable supply of artemisinin, an effective anti-malarial. Thanks to our breakthrough technology, these life saving drugs are more readily accessible.
Our initial business strategy was focused on the production of Biofene®, Amyris’s brand of renewable farnesene, a long-chain branched hydrocarbon molecule, manufactured using Amyris-engineered microbes in fermentation of plant sugar feedstock.
Building on the expertise from farnesene production, Amyris is developing, and in some cases producing, a range of other molecules. From these renewable molecules, we are developing a wide range of renewable specialty chemicals and fuels products, ranging from cosmetic emollients and fragrances to fuels and lubricants and even biopharmaceuticals, through our µPharm drug discovery platform."
https://amyris.com/our-company/
Styx...$3.25..excellent play here
$FDBL "Friendable" App Featured in Fifth Harmony Featuring Fetty Wap Music Video -- "Flex" 146+ Million Views
$AMRS "Our line of renewable lubricants will redefine performance for the lubricants industry by offering sustainably-sourced solutions to the most advanced lubrication challenges without compromise in performance or quality.
Amyris joined forces with Brazil’s Cosan to produce renewable base oils from Biofene. The Amyris-Cosan joint venture, named Novvi, will develop, produce, market and distribute high-performance renewable base oils, on a worldwide basis, for use in the lubricants market.
These renewable base oil and lubricants are designed to improve upon key environmental metrics including biodegradability, toxicity and renewability when compared with petroleum-sourced base oils, while delivering the high-performance characteristics of today’s leading oils." https://amyris.com/products/lubricants/
$LPTH is heating up folks - Conference Call 4:30 Eastern today afetr record Q's - Sar flipped yesterday
Amyris $AMRS and Ginkgo Bioworks partner; partnership is expected to generate over $300 million in incremental value for both
$AMRS Biogen. $BIIB Amyris nnounced partnership with Biogen, Inc. to develop alternative cell lines supporting production of therapeutics, marking second major partnership in biopharma market, which is now positioned to become Amyris’s largest opportunity for collaborations. The Biogen partenrship is the most exciting of all,” CEO John Melo said,. With it, Amyris he said would make “ a transformative change to biopharma where partner would be able to employ [Amyris biotechnology] instead of using cells from mammals. Others have attempted and failed, but we are positioned to deliver life saving therapeutics and make them more widely available. This could be game changing for biopharmaceuticals, and Biogen will fully fund the development.”
http://www.biofuelsdigest.com/bdigest/2016/08/14/amyris-the-new-colossus-aims-to-unlock-its-golden-door/
Amrs... ..44..on the move..
$DNRG slow and steady climb
$AMRS radar news coming!
Amrs....38...nice charts my opinion...
Amrs...looks ready..
$AMRS Huge buying about to start, again~
Orrp.. $1.80..looks to move higher...
Amrn. $2.25...nice play here...
$CUBA Golden Cross
$ERBB Medical Marijuana Vending Machines "ZaZZZ"
$AMRS Amyris Billionaire > Bill Gates Foundation Bought $5 Million of $AMRS Stock at $1.14 Per Share http://investors.amyris.com/releasedetail.cfm?releaseid=964449
Great link myopinion...
$CUBA Why You Should Invest in Cuba -- And How to Do It #CUBA
https://www.thestreet.com/story/13490830/1/why-you-should-invest-in-cuba-and-how-to-do-it.html
Amrs...huge bounce coming...
AMRS Hard to ignore this Monster past! $$
Great dd on Amrs..$1.00 test coming..
$AMRS [
In our first collaboration, Amyris developed technology capable of creating microbial strains to produce artemisinic acid — a precursor of artemisinin, an effective anti-malarial drug.
The Malaria Challenge
Malaria is a preventable disease that affects over a quarter of a billion people and claims the lives of hundreds of thousands of people every year, mostly children under the age of five in Africa. In addition to its debilitating impact on the health of populations in developing countries, malaria has also been shown to be a major constraint to economic development.
Malaria patients can be treated with highly effective Artemisinin-based Combination Therapies (ACTs), but cultivating and extracting artemisinin, which comes from the Chinese Sweet Wormwood plant, is expensive and time-consuming. Lack of access to this vital compound prevents millions of people in the developing world from receiving critical ACTs.
Semi Synthetic Artemisinin Process
The Artemisinin Project
Amyris first developed and applied our technology to create microbial strains that produce artemisinic acid, a precursor of artemisinin, a highly effective anti-malarial therapeutic. This work was funded by a grant awarded from the Bill & Melinda Gates Foundation via OneWorld Health (now PATH’s Drug Development Program).
Amyris is working to ensure access to affordable malaria treatments worldwide. In 2008, Amyris made available its Artemisinic Acid-producing yeast strains to Sanofi, via OneWorld Health, on a royalty-free basis. Sanofi began using this technology at large-scale to produce Artemisinin for ACT treatments with orginal plans to produce enough semi-synthetic Artemisinin for up to 150 million treatments by 2014 and ensure distribution under a “no profit, no loss” principle.
In 2013, Amyris scientists, working with others in their field, detailed this major breakthrough in the scientific journal Nature. In the journal article, scientists describe how they engineered simple Baker’s yeast strains to produce never before seen concentrations of artemisinic acid, the key ingredient for making this cure for malaria. The details of this breakthrough in microbial engineering and process development can be found in the online version of Nature.
?
The Artemisinin Project
Bill Gates on our technology to combat malaria.
https://amyris.com/collaborations/artemisinin/
Weyl..$1.80..if breaks $2.00.. watch it fly...
Thanks Zurich..and welcome to the board..getting this board more attention this coming year..check out my other 2 boards as well..and keep an eye on Nete...225..chart breaking starting...
Pphm...$1.18...on watch...
Good morning everyone..
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
308
|
Created
|
05/19/15
|
Type
|
Free
|
Moderator TommyBoyTrader9460 | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |